PH3 smells fishy.., page-3

Sell Down and Shorting in Feb Early March.

Yep, it appears that quite a few instos knew the outcome, not only the negative result itself, but also that it would land in March rather than April.

Back in May 2024, when the earlier‑than‑expected (and larger‑than‑expected) CR arrived immediately after a 20 % price slide for no apparent reason, demonstrated the fact that non disclosure agreements had the value of toliet paper. It only takes 1 to break their NDI. Just too much money can be made for a very hard to prove chrime.

Armed druggies can rob a servo and go to jail, but white‑collar crime based on information asymmetry still gets a free pass, some made stole millions. It only takes 1 to break the NDI and that looks to have happened.



Trial Failure.

None of the above, however, changes the disaster that is the Phase 3 read‑out—it’s absolutely perplexing, and the Phase 2b and Phase 3 data simply don’t square. If I were the DFA or Regal, I’d commission a truly independent, top‑to‑bottom review of the trial design and execution: verify the vial contents (purity and match to P2B) , and independently retest outcomes for 50 control patients versus 50 treated patients, where possible vitreous humor mass spectrometry to detect or not the existence OPT-302.